

Freie Universität Berlin
Fachbereich Humanmedizin
Universitätsklinikum Benjamin Franklin
Med. Klinik IV Endokrinologie und Nephrologie
Geschäftsführender Direktor: Prof. Zidek
Abteilung für Endokrinologie, Diabetes und Ernährungsmedizin
Abteilungsleiter: Prof. Pfeiffer

**The functions of growth factors in pituitary tumors
and their effect on IGF1 receptor regulation**

Inaugural-Dissertation
zur
Erlangung des Grades Doctor rerum medicarum
des Fachbereichs Humanmedizin
der Freien Universität Berlin

vorgelegt von: Adriana C. Drost
aus: Kozle (Polen)

Referent: Herr Prof. Dr. Hans-Jürgen Quabbe

Koreferent: Frau Prof. Dr. A. Grütters-Gieslich

Gedruckt mit Genehmigung des Fachbereichs Humanmedizin der Freien Universität
Berlin

Promoviert am 22. Oktober 2002

CONTENTS

Title	
Contents	3
Acknowledgements	8
List of Tables	9
List of Figures	10
Glossary	12
1. INTRODUCTION	14
1.1. Pituitary tumor etiology	14
1.2. Growth factor actions in the normal and tumorous pituitary	14
1.3. Primary aim of the project	15
1.3.1. Description of a rat pituitary tumor cell line	15
1.3.2. Primary cultures of human pituitary adenomas	16
1.4. Structure and function of IGF1 and its receptor	16
1.5. Secondary aim of the project	17
2. METHODS	18
2.1. Patient Information	18
2.2. Tumor preparation	18
2.2.1. Tumor extraction	18
2.2.2. Gel filtration chromatography	19
2.3. Cell culture	20

2.3.1. GH ₃ and HepG2 cell lines	20
2.3.2. Primary pituitary tumor cells (PP)	21
2.4. Bioassays	23
2.4.1. Preparation of tumor fractions, peptides and antibodies	23
2.4.2. ³ H-thymidine incorporation, cell numbers and hormone secretion in GH ₃ cells stimulated with growth factors, their neutralizing antibodies or tumor fractions	23
2.4.3. Stimulation of PP with growth factors	24
2.5. Hormone measurements	25
2.5.1. Rat GH radioimmunoassay (rGH RIA)	25
2.5.2. Rat Prolactin (rPRL) ELISA	25
2.6. Flow cytometry	25
2.6.1. Detection of apoptosis with Annexin V-FITC/Propidium iodide (AnnF/PI)	26
2.6.2. Detection of cell surface IGF1R receptors by flow cytometry	26
2.6.2.1. IGF1R labeling	26
2.6.2.2. Quantification of aIGF1R	26
2.6.2.3. Two-color IGF1R and cytokeratin labeling	28
2.6.2.4. Three-color AnnF/PI and IGF1R labeling	28
2.7. ¹²⁵ I-IGF1 competitive binding assay	29
3. RESULTS	30
3.1. Assay Optimization	30
3.1.1. GH ₃ bioassay optimization	30
3.1.1.1. Determination of optimal seeding concentration	30
3.1.1.2. GH ₃ cell survival under serum free conditions	31
3.1.1.3. ³ H-thymidine incorporation: optimal concentration and appropriate positive control	31
3.1.1.4. Determination of a positive control for stimulated hormone secretion	33
3.1.1.5. Time course of stimulated hormone secretion	34

3.1.2. Cytometric detection of apoptosis	35
3.1.2.1. Induction of apoptosis by serum deprivation	35
3.1.2.2. Induction of apoptosis with adenosine	36
3.1.3. Development of a new method for the semi-quantitative detection of cell surface IGF1R	37
3.1.3.1. Cytometric measurement of IGF1R expression	38
3.1.3.2. Detection of cell surface IGF1R expression in different cells	40
3.1.3.3. Detection of IGF1R expression in HepG2 cells after serum deprivation	41
3.1.3.4. Detection of IGF1R binding sites with ¹²⁵ I-IGF1 in HepG2 cells after serum deprivation	41
3.2. Effect of growth factors on ³ H-thymidine incorporation, apoptosis and hormone secretion in GH ₃ cells	44
3.2.1. ³ H-thymidine incorporation	44
3.2.2. Apoptosis	46
3.2.3. Hormone secretion	47
3.3. Detection of growth and secretion promoting activities in human pituitary tumor fractions	49
3.3.1. Pituitary tumor fractionation	49
3.3.2. Effect of human pituitary tumor fractions on ³ H-thymidine incorporation, cell numbers, apoptosis and hormone secretion in GH ₃ cells	50
3.3.2.1. ³ H-thymidine incorporation and cell numbers	51
3.3.2.2. Apoptosis	52
3.3.2.3. Hormone secretion	52
3.3.3. Stimulatory activities in tumor fractions of null cell adenomas (NCA) and of hormone secreting adenomas	57
3.3.4. Neutralization of pituitary tumor induced stimulatory activities	58

3.3.4.1.	Determination of optimal antibody concentrations, which neutralize growth factor-induced stimulation in GH ₃ cells	58
3.3.4.2.	Effects of neutralizing antibodies specific against growth factors on pituitary tumor fraction induced ³ H-thymidine incorporation in GH ₃ cells	61
3.3.4.3.	Effects of neutralizing antibodies specific against growth factors on pituitary tumor fraction induced hormone secretion	62
3.4.	Functional effects of growth factors on primary human pituitary cells	63
3.4.1.	Effect of serum deprivation on apoptosis in PP	63
3.4.2.	Effect of growth factors on apoptosis in PP	64
3.4.3.	Effect of neutralizing growth factor antibodies on apoptosis in PP	65
3.5.	IGF1R studies in PP	67
3.5.1.	Effect of serum deprivation on IGF1R expression in PP	67
3.5.2.	Effect of growth factors on IGF1R expression in PP	68
3.5.3.	Concentration- and time dependent IGF1R modulation	68
4.	DISCUSSION	71
4.1.	Major aims and results	71
4.2.	Discussion of effects of growth factors on <u>proliferation and apoptosis</u> in pituitary tumor cells	71
4.2.1.	bFGF	72
4.2.2.	EGF	72
4.2.3.	IGF1	72
4.2.4.	IL2	73
4.2.5.	IL6	73
4.3.	Discussion of effects of growth factors on <u>hormone secretion</u> in pituitary tumor cells	74
4.3.1.	bFGF	74
4.3.2.	EGF	75

4.3.3. IGF1	76
4.3.4. IL2	77
4.3.5. IL6	77
4.4. Discussion of the demonstration of growth factor-like activities in human pituitary tumors	78
4.4.1. Discussion of findings on human pituitary fractions as related to known growth factors	81
4.5. Discussion of findings on human pituitary tumor fractions as related to clinical and histological diagnoses	81
4.6. Comparison of apoptosis induction in GH ₃ cells and PP by serum deprivation	82
4.7. Discussion of the new method to detect cell surface IGF1 receptors by flow cytometry	83
4.8. Discussion of IGF1R regulation in PP	84
5. SUMMARY	85
6. REFERENCES	87

Acknowledgements

For his continuous support and patience I thank Prof. Dr. med. Hans-Jürgen Quabbe, who served as the project supervisor during the initial two years. Moreover, he was my doctoral advisor and I am particularly thankful for his aid and effort even after he became emeritus professor. My appreciation also goes to Dr. Ursula Plöckinger, who was the project supervisor during the remaining years. Her support and trust in my ability to work independently enabled the development of new techniques and facilitated my creative scientific thinking. Without her this project would not have been completed, since she facilitated our move to a new laboratory at the Humboldt University, Charité, Campus Virchow-Klinikum, where she took a new position.

I also thank Dr. Mark Lewis, Prof. Dr. med Michael Buchfelder, Prof. Dr. med. Andreas Unterberg and Prof. Dr. med. Zirsky for their collaboration in this project. They provided us with human pituitary tumors and offered helpful scientific and/or clinical comments.

For their excellent technical assistance I would like to thank Margit Rösick and Marina Rochel, who also helped with the training and supervision of three medical doctoral students. My appreciation is extended to these students, Manuela Jänike, Matthias Binder and Hartmut Böhm, who assisted with some of the tedious laboratory work and helped to create a relaxed and fun atmosphere in the laboratory.

Meinen Freunden und meiner Familie möchte ich von Herzen für ihre Unterstützung, Geduld und Liebe danken; ihr Zuspruch gab mir die notwendige Ausdauer um diese Doktorarbeit zu beenden.

List of Tables

- Table 2.1. Demographics of patients, whose tumor tissue was extracted and separated by gel filtration chromatography
- Table 2.2. Demographics of patients, whose tumor tissue was prepared into primary culture
- Table 3.2.1. Summary of growth factors potentially participating in pituitary tumor development and growth
- Table 3.2.2. Peptide-induced ³H-thymidine uptake of GH₃ cells
- Table 3.2.3. Summary of the effects of growth factors on GH₃ cells
- Table 3.3.1. Percentage of tumor fractions from extracts of all pituitary adenomas containing stimulatory activities
- Table 3.3.2. Percentage of tumor fractions from extracts of null cell adenomas containing stimulatory activities
- Table 3.3.3. Percentage of tumor fractions from extracts of hormone secreting adenomas containing stimulatory activities
- Table 3.3.5. Antibodies used for neutralization of peptide-induced stimulations
- Table 3.4.1. Effect of growth factors on apoptosis of PP from several human pituitary adenomas
- Table 3.4.3. Effect of neutralizing growth factor antibodies on apoptosis of PP from several human pituitary adenomas

List of Figures

- Figure 2.1. Calibration curve of a Superdex 30 column
- Figure 2.2. Quantification of anti IGF1R antibody binding
- Figure 3.1.1. Growth of GH₃ cells in C-DM/F12 (A) or in SF-DM/F12 (B)
- Figure 3.1.2. Effect of adenosine (AD) on ³H-thymidine incorporation of GH₃ cells.
- Figure 3.1.3. TRH induced PRL (A) and GH (B) secretion in GH₃ cells
- Figure 3.1.4. Kinetics of TRH induced PRL (A) and GH (B) secretion in GH₃ cells
- Figure 3.1.5. Effect of serum deprivation on apoptosis in GH₃ cells
- Figure 3.1.6. Apoptosis in GH₃ cells
- Figure 3.1.7. Titration curves of primary antiIGF1R (A) and secondary DAM-PE (B)
- Figure 3.1.8. Titration of antiIGF1R on different cell types
- Figure 3.1.9. IGF1R expression in different cell types
- Figure 3.1.10. IGF1R expression in HepG2 cells
- Figure 3.1.11. Competitive binding of ¹²⁵I-IGF1 on HepG2 cells
- Figure 3.1.12. IGF1 binding on HepG2 cells after serum deprivation
- Figure 3.2.1. Effect of growth factors on ³H-thymidine incorporation of GH₃ cells
- Figure 3.2.2. Effect of growth factors on apoptosis in GH₃ cells
- Figure 3.2.3. Effect of growth factors on hormone secretion of GH₃ cells
- Figure 3.3.1. Elution of a human pituitary tumor extract on a Superdex 30 column
- Figure 3.3.2. Pituitary tumor fraction-induced ³H-thymidine incorporation and cell numbers of GH₃ cells
- Figure 3.3.3. Pituitary tumor fraction-induced protection from apoptosis of GH₃ cells
- Figure 3.3.4. Hormone secretion of GH₃ cells induced by pituitary tumor fractions
- Figure 3.3.5. ³H-thymidine- and cell number-augmenting activities in chromatography fractions of 10 human pituitary tumors
- Figure 3.3.6. Hormone secretion-inducing activities in chromatography fractions of 10 human pituitary tumors

- Figure 3.3.7. Effect of neutralizing growth factor antibodies on ³H-thymidine incorporation of GH₃ cells
- Figure 3.3.8. Effect of neutralizing growth factor antibodies on PRL (A) and GH (B) secretion of GH₃ cells
- Figure 3.3.9. Effects of neutralizing growth factor antibodies on ³H-thymidine-inducing activities of pituitary tumor fractions
- Figure 3.3.10. Effects of antiIL6 on GH-inducing activities of pituitary tumor fractions
- Figure 3.4.1. Effect of serum deprivation on apoptosis of PP
- Figure 3.5.1. Effect of serum deprivation on IGF1R expression in PP
- Figure 3.5.2. Effect of growth factors on IGF1R expression in PP
- Figure 3.5.3. Dose-dependent ligand mediated IGF1R regulation in PP
- Figure 3.5.4. Time-dependent ligand mediated IGF1R

Glossary

<i>Abbreviation</i>	<i>Meaning</i>
ABC	Antigen binding capacity
Acro	acromegaly
aIGF1R	anti insulin like growth factor receptor antibody
AnnF	Annexin V-FITC
AnnF/PI	Annexin V-FITC/propidium iodide
BB	Binding buffer
bFGF	basic fibroblast growth factor
BSA	bovine serum albumin
C-DM/F12	complete DM/F12
Cor	Corticotropinoma
C-PPM	complete primary pituitary cell medium
Cush	Cushing syndrome
DAM-PE	donkey anti mouse antibody, phytoerythrin conjugated
DM/F12	Dulbecco's Modified Earl medium and F12 medium at 1:2
EDTA	Ethylene diamine tetraacetic acid
EGF	epidermal growth factor
f	female
FCS	Fetal calf serum
FITC	Fluorescein Isothiocyanate
GF	Growth factors
GH	Growth hormone
GH ₃	Rat pituitary tumor cell line
Gon	Gonadotropinoma
hnIL6	Human natural interleukin 6
hrbFGF	Human recombinant basic fibroblast growth factor
hrEGF	Human recombinant epidermal growth factor
hrlGF1	human recombinant insulin like growth factor-1
hrlL2	human recombinant interleukin-2
HS	Horse serum

IGF1	Insulin like growth factor-1
IGF1R	Insulin like growth factor Type 1 receptor
IgG	Immunoglobulin G
IL2	Interleukin-2
IL6	Interleukin-6
m	Male
NaOH	Sodium hydroxide
NCA	Null cell adenoma
Neg	Negative control
NFA	Non functioning adenoma
NIDDK	National institute for Diabetes and Digestive Disorders
Null	Null cell adenoma
PBS	Phosphate buffered saline
PE	Phytoerythrin
PI	Propidium iodide
Pluri	Plurihormonal adenoma
Pos	Positive control
PP	Primary human pituitary cells
PRL	Prolactin
Prol	Prolactinoma
RGH	Rat growth hormone
RGH RIA	Rat growth hormone radio immunoassay
rPRL	Rat prolactinoma
RT	Room temperature
SABC	Specific antigen binding capacity
SF-DM/F12	Serum free DM/F12
Som	Somatotropinoma
TRH	Thyrotropin releasing hormone

LEBENS LAUF

10. Dez. 2002

Adriana C. Drost

Handjerystr. 42, 12159 Berlin

Tel: (030) 785 5205

geboren am 10. Januar 1963, ledig, 1 Sohn

ARBEITSERFAHRUNG

1982	<u>Stadtkrankenhaus Leonberg</u>	Krankenpflegepraktikantin
1982-1983	<u>Landratsamt Böblingen</u>	Sachbearbeiterin
1986-1988	<u>Mashall University</u> , Huntington, West Virginia, USA	Wissenschaftliche Assistentin
1989-1995	<u>US Army Institute of Surgical Research</u> , Fort Sam Houston, Texas, USA	Wissenschaftliche Mitarbeiterin
1996-03/1999	<u>Universitätsklinikum Benjamin Franklin</u> , Berlin	Wissenschaftliche Mitarbeiterin
04/1999-10/2001	<u>Humboldt Universität zu Berlin</u> , Campus Virchow Klinikum	Wissenschaftliche Mitarbeiterin

FORSCHUNGSPROJEKTE

Systematische Studie zur Rolle von Wachstumsfaktoren und des IGF1R in humanen Hypophysenadenomen

Mehrjährige Patientenstudie über klinische und immunologische Auswirkungen von Omega-3-Fettsäure-supplementierungen in künstlich ernährten Brandpatienten

Analyse entzündlicher Zytokinen (IL1, IL6, TNF) bei Infektionen und Sepsis von Brandpatienten

Untersuchung von Aktivationszuständen in Granulozyten bei Brandpatienten

Studium von MHC-Komplexen und Antigenpresentation von Monozyten nach Brandverletzungen

Der Einfluß von Stickoxyd auf die Oxidationskapazität von Granulozyten

Auswirkungen von Pentoxifylline auf verschiedene Granulozytenfunktionen

Isolierung von Interleukin-1 aus Ratten-Plasma und dessen Rolle in Infektion und Sepsis

Aufbau eines Forschungslaboratoriums

LABORTECHNIKEN

Zell- und Primärkulturexpertise

Immunologische Bioassays (z.B. Mixed Lymphocyte Reaction, CTLL-reaktion, LBRM-assay)

Proliferations- und Apoptosenachweise

Proteinisolierung und -bestimmung (HPLC, Gelchromatographie)

Durchflußzytometrie (Facstar und FACSCAN, CALIBUR)

Messung des Polymerisationszustandes von Aktinfilamenten in Granulozyten

Oxidationsmessungen in Granulozyten und Monozyten (O_2^- , H_2O_2)

Chloramin-T Markierung von Peptiden mit 125 Jodid

ELISA and RIA

EDV-KENNTNISSE

Computersysteme: PC, Macintosh, Mainframe/VMS

Software: Microsoft Office, QuattroPro, Lotus, Sigmaplot, dBase, VPI, BMDP

Datenbankaufbau und -verwaltung unter dBaseclone VPI

Standardisierung und Automatisierung neuer Laborarbeiten mit komplexer Computertechnologie

Nutzung und Wartung computergesteuerter Laborinstrumente

AUSBILDUNG

1969-1982	Grundschule und Gymnasium in Böblingen
1982	14.5., <u>Abitur</u> , Otto-Hahn Gymnasium Böblingen
1983-1985	Biologiestudium, Eberhard-Karls-Universität Tübingen
1985	9.8., <u>Vordiplom in Biologie</u> , Eberhard-Karls-Universität Tübingen
1985-1986	Austauschstudium, Marshall University, West Virginia, USA
1986-1988	Studium in Biomedical Sciences, Marshall University, West Virginia, USA
1987-1988	Diplomarbeit, "Effects of Thermal Injury on Plasma Interleukin-1 Activity in Burned Rats."
1988	16.12., <u>Master of Science in Biomedical Sciences</u> (equivalent zum Diplom in Humanbiologie), Marshall University, West Virginia, USA

- 1988 16.12., Auszeichnung für akademische Leistungen, Marshall University, USA
 1999-2002 Promotionarbeit „The functions of growth factors in pituitary tumors and their effect on IGF1 receptor regulation.“
 2002 22.10., Doktor rerum medicarum des Fachbereiches Humanmedizin, Freie Universität Berlin

PROFESIONELLE ORGANISATION

Society of Leukocyte Biology
 Deutsche Gesellschaft für Endokrinologie

VERÖFFENTLICHUNGEN

MANUSKRIPTE

The Effects of Thermal Injury on Serum Interleukin 1 Activity in Rats. A.C. Drost, B. Larsen, H.L. Aulick. Lymphokine and Cytokine Research. 12(3):181-5. 1993

Plasma Cytokines following Thermal Injury and their Relationship with Patient Mortality, Burn Size, Time Postburn. A.C. Drost, D. Burleson, W.G. Cioffi, Jr., B.S. Jordan, A.D. Mason, Jr., B.A. Pruitt, Jr. J.Trauma. 35(3):335-9. 1993

Plasma Cytokines following Thermal Injury and their Relationship to Infection. A.C. Drost, D. Burleson, W.G. Cioffi, Jr., A.D. Mason, Jr., B.A. Pruitt, Jr. Annals of Surgery. 218(1):74-8. 1993

Humoral Manifestations of Regulation and Dysregulation of the Systemic Mediator Response in Injury and Sepsis. B.A. Pruitt, Jr., D.G. Burleson, A.C. Drost, W.G. Cioffi, Jr., A.D. Mason, Jr. Proceedings of the 3rd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. 1994.

Interferon- γ inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. K.M. Detjen, J. P. Kehrberger, A. Drost, A. Rabien, M. Welzel, B. Wiedenmann, S. Rosewicz. (submitted for publication Jul 2001)

Autocrine/paracrine regulation of apoptosis in pituitary tumor cells: Importance of growth factors bFGF, EGF, IGF1, and IL6. A.C. Drost, H.-J. Quabbe, A. Unterbrg, M. Buchfelder, B. Wiedenmann, U. Plöckinger. (submitted for publication, Europ. J. Endocrinol. Oct 2001)

ABSTRAKTE

Interleukin 1 (IL1) Activity in the Serum of Burned Rats. A.C. Drost, B. Larsen, H.L. Aulick. The FASEB Journal. 3(1):A319, 1989.

Plasma Interleukin 1 β (IL1 β) Following Thermal Injury Measured by ELISA. A.C. Drost, D. Burleson, A.D. Mason, Jr., B.A. Pruitt, Jr. The FASEB Journal. 1990.

Plasma Interleukin 1 and Interleukin 6 Concentrations Following Thermal Injury and their Relationship to Patient Survival. A.C. Drost, D. Burleson, A.D. Mason, Jr., B.A. Pruitt, Jr. Abstracts, 2nd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. pg. 62:OP55. 1991.

The Relationship between Plasma Cytokine Levels, Burn Size and Time after Burn. D.G. Burleson, A.C. Drost, A.D. Mason, Jr., B.A. Pruitt, Jr. Abstracts, 2nd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. pg. 101:P50, 1991

The Relationship of Plasma Cytokines to Infection following Thermal Injury. A.C. Drost, D.G. Burleson, W.G. Cioffi, Jr., A.D. Mason, Jr., B.A. Pruitt, Jr. J. Immunology 150(8):293A. 1993.

The Relationship of Granulocyte F-Actin Levels and Infection following Thermal Injury. A.C. Drost, W.G. Cioffi, Jr., G.J. Carrougher, A.D. Mason, Jr., B.A. Pruitt, Jr. Intensive Care Medicine. 20(Suppl. 1):S36, 1994

Altered Actin Polymerization in Granulocytes following Thermal Injury. A.C. Drost, W.G. Cioffi, Jr., G. Carrougher, D.G. Burleson, A.D. Mason, Jr., B.A. Pruitt, Jr. Proceedings of the American Burn Association. 26:26. 1994

Altered Granulocyte H₂O₂ Release following Severe Thermal Injury. A.C. Drost, R. Moore, A.D. Mason, Jr., B.A. Pruitt, Jr., W.G. Cioffi, Jr. (accepted for publication, FASEB 1995)

Growth Factor-Like Activities in Human Pituitary Adenomas. A.C. Drost, U. Plöckinger, M. Jänike, M. Binder, M.D. Lewis, M.F. Scanlon, H.-J. Quabbe. Exp. And Clinic. Endocrinology and Diabetes. 107, Suppl. 1. 1999

Growth factor-like activities in human pituitary adenomas. A.C: Drost, U. Plöckinger, M. Jänike, M. Binder, M.D. Lewis, M.F. Scanlon, H.-J. Quabbe. DGE 1999 in Kiel.

Cell surface IGF-IR expression and apoptosis measured by flowcytometry in rat pituitary tumor cells (GH₃). A.C. Drost, U. Plöckinger, H.-J. Quabbe. ENDO 1999 in San Diego CA; USA

IGF-1 induced activation of L-Type Ca²⁺ channels in human NE primary cell cultures and permanent cell lines is different. S. Mergeler, A. C. Drost, und B. Wiedenmann. Gastroenterology, Suppl. to April 2000 issue, Abtr# 2842

IGF1 receptor modulation in primary pituitary tumor cells. A.C. Drost, U. Plöckinger, A. Unterberg, H.-J. Quabbe, B. Wiedenmann. DGE 2001 in Magdeburg

Growth factors modulate apoptosis of human and rat pituitary tumor cells. A.C. Drost, A. Unterberg, H.J. Quabbe, M. Buchfelder, B. Wiedenmann, U. Plöckinger. ENDO 2001 in Atlanta, GA, USA